Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit
- 1 February 2018
- journal article
- research article
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 221, 46-51
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche Belgium
This publication has 11 references indexed in Scilit:
- Abstract P4-21-15: Trastuzumab IV versus SC: A time, motion and cost assessment in a lean operating day care oncology unitCancer Research, 2017
- Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare settingThe Breast, 2016
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831Journal of Clinical Oncology, 2014
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyThe Lancet Oncology, 2013
- Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast CancerThe Journal of Clinical Pharmacology, 2013
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trialThe Lancet Oncology, 2012
- Lean oncology: a new model for oncologistsJournal of Translational Medicine, 2012
- Treatment of HER2-overexpressing breast cancerAnnals of Oncology, 2010
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005